Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 28, 2017

Study Completion Date

August 28, 2017

Conditions
Alzheimer's Disease
Interventions
DRUG

Flortaucipir F18

370 megabecquerel (MBq) IV single-dose

PROCEDURE

PET Scan

positron emission tomography (PET) scan

Trial Locations (22)

10016

New York University Center for Brain Health, New York

19104

University of Pennsylvania, Philadelphia

27710

Duke University Medical Center, Durham

32806

Compass Research, LLC, Orlando

33407

Premiere Research Institute, West Palm Beach

33613

University of South Florida Health Byrd Alzheimer's Institute, Tampa

33709

Meridien Research, St. Petersburg

33912

Neuropsychiatric Research Center of Southwest Florida, Fort Myers

63110

Washington University School of Medicine, St Louis

85006

Banner Alzheimer's Institute, Phoenix

85258

Imaging Endpoints, Scottsdale

85259

Mayo Clinic Arizona, Scottsdale

85351

Banner Sun Health Research Institute, Sun City

89113

Las Vegas Radiology, Las Vegas

90404

California Medical Clinic for Headache, Santa Monica

92663

21st Century Oncology, Newport Beach

92697

Institute for Brain Aging and Dementia, UC Irvine, Irvine

95817

Alzheimer's Disease Center, UC Davis, Sacramento

02114

Massachusetts General Hospital, Boston

02118

Boston University School of Medicine, Boston

02903

Rhode Island Hospital, Providence

02906

Butler Hospital, Providence

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY